Clinical Trial Update: A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD [Phase 2]

View source ↗

Summary

Phase 2a study of TPN-101 in patients with C9ORF72-associated ALS/FTD has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis
• Frontotemporal Dementia

Drugs mentioned

• TPN-101

Snippet

Sponsor: Transposon Therapeutics, Inc. | Conditions: Amyotrophic Lateral Sclerosis, Frontotemporal Dementia | Phase 2 | Status: COMPLETED